These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

743 related items for PubMed ID: 31627834

  • 1. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, Lavie CJ, Fonarow GC, Aneja A.
    Am J Cardiol; 2019 Dec 01; 124(11):1790-1796. PubMed ID: 31627834
    [Abstract] [Full Text] [Related]

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb 01; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 3. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
    Scheen AJ.
    Rev Med Suisse; 2020 Aug 26; 16(703):1483-1488. PubMed ID: 32852168
    [Abstract] [Full Text] [Related]

  • 4. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y, Kuwahara K.
    J Cardiol; 2020 Aug 26; 76(2):123-131. PubMed ID: 32340780
    [Abstract] [Full Text] [Related]

  • 5. Dapagliflozin for heart failure: is it a class effect?
    Raj GM, Wyawahare M.
    Future Cardiol; 2021 Mar 26; 17(2):355-361. PubMed ID: 32755319
    [Abstract] [Full Text] [Related]

  • 6. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI.
    Circulation; 2017 Oct 24; 136(17):1643-1658. PubMed ID: 29061576
    [Abstract] [Full Text] [Related]

  • 7. Current Role of Dapagliflozin in Clinical Practice.
    Zargar AH, Trailokya AA, Ghag S, Pawar R, Aiwale A, Zalke A.
    J Assoc Physicians India; 2021 Sep 24; 69(9):11-12. PubMed ID: 34585897
    [Abstract] [Full Text] [Related]

  • 8. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 9. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S.
    Crit Pathw Cardiol; 2017 Sep 19; 16(3):93-95. PubMed ID: 28742644
    [Abstract] [Full Text] [Related]

  • 10. SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
    Kumar K, Behl T, Kumar A, Arora S.
    Curr Mol Pharmacol; 2021 Oct 25; 14(4):487-497. PubMed ID: 33045972
    [Abstract] [Full Text] [Related]

  • 11. [Outcome studies on SGLT-2 inhibitors].
    Seufert J, Laubner K.
    Internist (Berl); 2019 Sep 25; 60(9):903-911. PubMed ID: 31375850
    [Abstract] [Full Text] [Related]

  • 12. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H, Nester W, Elgendy IY, Saad M.
    Ann Med; 2020 Aug 25; 52(5):178-190. PubMed ID: 32393068
    [Abstract] [Full Text] [Related]

  • 13. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS, Correa A, Contreras JP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):311-321. PubMed ID: 34264341
    [Abstract] [Full Text] [Related]

  • 14. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L.
    Heart Fail Rev; 2018 May 05; 23(3):409-418. PubMed ID: 29704192
    [Abstract] [Full Text] [Related]

  • 15. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M.
    Cardiovasc Diabetol; 2019 Oct 04; 18(1):129. PubMed ID: 31585532
    [Abstract] [Full Text] [Related]

  • 16. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A.
    Front Endocrinol (Lausanne); 2023 Oct 04; 14():1216160. PubMed ID: 38179304
    [Abstract] [Full Text] [Related]

  • 17. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M, D'Amario D, Sofia C, Vaccarella M, Crea F, Aspromonte N.
    Expert Opin Drug Metab Toxicol; 2018 Dec 04; 14(12):1273-1285. PubMed ID: 30472914
    [Abstract] [Full Text] [Related]

  • 18. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.
    Circulation; 2016 Sep 06; 134(10):752-72. PubMed ID: 27470878
    [Abstract] [Full Text] [Related]

  • 19. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
    Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E.
    Curr Cardiol Rev; 2020 Sep 06; 16(4):258-265. PubMed ID: 31362691
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD, EMPERIAL Investigators and National Coordinators.
    Eur J Heart Fail; 2019 Jul 06; 21(7):932-942. PubMed ID: 31218819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.